Patent · US Active

Treatment of amyotrophic lateral sclerosis

US10590420B2 · kind B2 · utility

2Cited by

0References

34Claims

0Family size

Assignees

ASSOCIATION INSTITUT DE MYOLOGIE · FR
Institut National de la Sante et de la Recherche Medicale (INSERM) · FR
Universite Pierre Et Marie Curie (Paris 6) · FR

Inventors

Martine Barkats · Charenton-le-Pont, FR
MARIA-GRAZIA BIFERI · Paris, FR
Thomas Voit · Gif-sur-Yvette, FR

Key dates

Filing date	Jul 31, 2015
Grant date	Mar 17, 2020
Priority date	—
Expiry date	Jul 31, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2799/025
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to a method for the treatment of amyotrophic lateral sclerosis (ALS). Specifically, the invention implements the use of an antisense sequence adapted to affect alternative splicing in a human SOD1 pre-mRNA, thereby leading to the destruction of the skipped m RNA by the cell machinery.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.